GMDA News and Press, Gamida Cell Ltd. From 12/14/20

Aerpio Pharmaceuticals ARPO -43% after announcing results from Razuprotafib Glaucoma Phase 2 Trial.Greenwich LifeSciences (GLSI) -18%.Gamida Cell (GMDA) -18% on providing regulatory update on biologics license application for Omidubicel.Virgin Galactic Holdings SPCE -...

-- Feedback from FDA supports proceeding to BLA Submission for omidubicel with additional manufacturing requirements; the company plans to submit full BLA in second half of 2021 Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for ...

Gamida Cell (NASDAQ: GMDA) and its approach to attacking cancer with natural killer cells faded into the shadows shortly after the company's stock market debut in 2018. After years of languishing, clinical trial results presented during a virtual scientific conference recently prope...

Giving a pipeline update, Gamida Cell (NASDAQ:GMDA) reaffirms the clinical success of its cell therapy candidate, omidubicel in a Phase 3 study evaluating the safety and efficacy in patients with hematologic malignancies (blood cancers).Under development as an allogeneic hematopoietic st...

—Omidubicel results in improved clinical outcomes as measured by reduction in time to neutrophil engraftment, time in hospital and infections following bone marrow transplant— — Company announces omidubicel commercial readiness plan, including the creation...

Gainers: Obalon Therapeutics (OBLN) +121%.Greenland Technologies (GTEC) +79%.Oncternal Therapeutics (ONCT) +61%.Eastman Kodak (KODK) +60%.Fate Therapeutics (FATE) +46%.Nkarta (NKTX) +44%.Constellation Pharmaceuticals (CNST) +34%.Gamida Cell (GMDA) +31%.EHang Holdings (EH) +30%.Tonix...

—GDA-201 was well-tolerated and no dose-limiting toxicities were observed— —GDA-201 demonstrated significant clinical activity in patients with non-Hodgkin lymphoma, with multiple complete responses observed— —Phase 2 clinical trial o...

- Focused on omidubicel, an advanced cell therapy, including a review of Phase 3 clinical data, and GDA-201, a natural killer cell therapy – - Event to feature an omidubicel patient’s perspective - - Live webcast on December 9, 2020 at 8:00 a.m. ET - ...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Chief Executive Officer of Gamida Cell, will present at two virtual conferences in December: Evercore ISI 3 rd ...

Gamida Cell Ltd (GMDA) Q3 2020 Earnings Conference Call November 10, 2020, 08:30 ET Company Participants Joshua Hamermesh - Chief Business Officer Julian Adams - CEO & Director Ronit Simantov - Chief Medical Officer Shai Lankry - CFO Michele Korfin - Chief Operating & Chief Commercial...